Literature DB >> 24442146

Combined effects of a high-fat diet and chronic valproic acid treatment on hepatic steatosis and hepatotoxicity in rats.

Li-fang Zhang1, Ling-sheng Liu1, Xiao-man Chu2, Hao Xie1, Li-juan Cao1, Cen Guo1, Ji-ye A1, Bei Cao1, Meng-jie Li1, Guang-ji Wang1, Hai-ping Hao1.   

Abstract

AIM: To investigate the potential interactive effects of a high-fat diet (HFD) and valproic acid (VPA) on hepatic steatosis and hepatotoxicity in rats.
METHODS: Male SD rats were orally administered VPA (100 or 500 mg·kg⁻¹·d⁻¹) combined with HFD or a standard diet for 8 weeks. Blood and liver samples were analyzed to determine lipid levels and hepatic function biomarkers using commercial kit assays. Low-molecular-weight compounds in serum, urine and bile samples were analyzed using a metabonomic approach based on GC/TOF-MS.
RESULTS: HFD alone induced extensive hepatocyte steatosis and edema in rats, while VPA alone did not cause significant liver lesions. VPA significantly aggravated HFD-induced accumulation of liver lipids, and caused additional spotty or piecemeal necrosis, accompanied by moderate infiltration of inflammatory cells in the liver. Metabonomic analysis of serum, urine and bile samples revealed that HFD significantly increased the levels of amino acids, free fatty acids (FFAs) and 3-hydroxy-butanoic acid, whereas VPA markedly decreased the levels of amino acids, FFAs and the intermediate products of the tricarboxylic acid cycle (TCA) compared with the control group. HFD aggravated VPA-induced inhibition on lipid and amino acid metabolism.
CONCLUSION: HFD magnifies VPA-induced impairment of mitochondrial β-oxidation of FFAs and TCA, thereby increases hepatic steatosis and hepatotoxicity. The results suggest the patients receiving VPA treatment should be advised to avoid eating HFD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24442146      PMCID: PMC4647887          DOI: 10.1038/aps.2013.135

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  52 in total

1.  Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.

Authors:  Tianlu Chen; Guoxiang Xie; Xiaoying Wang; Jia Fan; Yunping Qiu; Xiaojiao Zheng; Xin Qi; Yu Cao; Mingming Su; Xiaoyan Wang; Lisa X Xu; Yun Yen; Ping Liu; Wei Jia
Journal:  Mol Cell Proteomics       Date:  2011-04-25       Impact factor: 5.911

2.  Dietary intake patterns are reflected in metabolomic profiles: potential role in dietary assessment studies.

Authors:  Aifric O'Sullivan; Michael J Gibney; Lorraine Brennan
Journal:  Am J Clin Nutr       Date:  2010-12-22       Impact factor: 7.045

3.  Global analysis of metabolites in rat and human urine based on gas chromatography/time-of-flight mass spectrometry.

Authors:  A Jiye; Qing Huang; Guangji Wang; Weibin Zha; Bei Yan; Hongcan Ren; Shenghua Gu; Ying Zhang; Qi Zhang; Feng Shao; Longsheng Sheng; Jianguo Sun
Journal:  Anal Biochem       Date:  2008-04-23       Impact factor: 3.365

4.  A new approach on valproic acid induced hepatotoxicity: involvement of lysosomal membrane leakiness and cellular proteolysis.

Authors:  Jalal Pourahmad; Mohammad Reza Eskandari; Amineh Kaghazi; Fatemeh Shaki; Jafar Shahraki; Javad Khalili Fard
Journal:  Toxicol In Vitro       Date:  2012-02-08       Impact factor: 3.500

5.  Nonalcoholic fatty liver disease in adolescents receiving valproic acid.

Authors:  Alberto Verrotti; Sergio Agostinelli; Pasquale Parisi; Francesco Chiarelli; Giangennaro Coppola
Journal:  Epilepsy Behav       Date:  2011-01-20       Impact factor: 2.937

6.  In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions.

Authors:  S Ponchaut; F van Hoof; K Veitch
Journal:  Biochem Pharmacol       Date:  1992-06-09       Impact factor: 5.858

7.  In vitro study of the antioxidative properties of the glucose derivatives against oxidation of plasma components.

Authors:  Joanna Kolodziejczyk; Joanna Saluk-Juszczak; Barbara Wachowicz
Journal:  J Physiol Biochem       Date:  2010-11-19       Impact factor: 4.158

8.  Characterization of post-surgical alterations in the bile duct-cannulated rat.

Authors:  Dalila Bachir-Cherif; Denise Blum; Annamaria Braendli-Baiocco; Evelyne Chaput; Gonzalo Christiano Duran Pacheco; Nicholas Flint; Monika Haiker; Jean-Christophe Hoflack; Nicole Justies; Rachel Neff; Volkmar Starke; Guido Steiner; Charles Alexandre Tournillac; Thomas Singer; Geneviève Ubeaud-Séquier; Franz Schuler
Journal:  Xenobiotica       Date:  2011-04-27       Impact factor: 1.908

9.  Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores.

Authors:  Andrea Caroline Knapp; Liliane Todesco; Konstantin Beier; Luigi Terracciano; Hans Sägesser; Jürg Reichen; Stephan Krähenbühl
Journal:  J Pharmacol Exp Ther       Date:  2007-11-06       Impact factor: 4.030

Review 10.  Non-alcoholic fatty liver disease: the mist gradually clears.

Authors:  Nimantha Mark Wilfred de Alwis; Christopher Paul Day
Journal:  J Hepatol       Date:  2008-02-04       Impact factor: 25.083

View more
  10 in total

1.  Valproic Acid and Hepatic Steatosis: A Possible Link? About a Case Report.

Authors:  Leila Mnif; Rim Sellami; Jawaher Masmoudi
Journal:  Psychopharmacol Bull       Date:  2016-08-15

Review 2.  Role of xenobiotics in the induction and progression of fatty liver disease.

Authors:  James E Klaunig; Xilin Li; Zemin Wang
Journal:  Toxicol Res (Camb)       Date:  2018-05-18       Impact factor: 3.524

3.  Microphysiological flux balance platform unravels the dynamics of drug induced steatosis.

Authors:  Avner Ehrlich; Sabina Tsytkin-Kirschenzweig; Konstantinos Ioannidis; Muneef Ayyash; Anne Riu; Reine Note; Gladys Ouedraogo; Jan Vanfleteren; Merav Cohen; Yaakov Nahmias
Journal:  Lab Chip       Date:  2018-08-21       Impact factor: 6.799

Review 4.  Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease.

Authors:  Liane Rabinowich; Oren Shibolet
Journal:  Biomed Res Int       Date:  2015-07-26       Impact factor: 3.411

5.  Hepatic gene expression explains primary drug toxicity in bipolar disorder.

Authors:  Serge Weis; Johannes Haybaeck; Anna Maria Birkl-Toeglhofer; Christoph Birkl; Ida Cirila Llenos
Journal:  Transl Psychiatry       Date:  2019-12-09       Impact factor: 6.222

6.  NMR-based metabolomics in pediatric drug resistant epilepsy - preliminary results.

Authors:  Łukasz Boguszewicz; Ewa Jamroz; Mateusz Ciszek; Ewa Emich-Widera; Marek Kijonka; Tomasz Banasik; Agnieszka Skorupa; Maria Sokół
Journal:  Sci Rep       Date:  2019-10-21       Impact factor: 4.379

7.  Protective Effect of Thyme Honey against Valproic Acid Hepatotoxicity in Wistar Rats.

Authors:  Rezvan Omidipour; Leila Zarei; Mandana Beigi Boroujeni; Asghar Rajabzadeh
Journal:  Biomed Res Int       Date:  2021-02-20       Impact factor: 3.411

8.  Potential of the zebrafish (Danio rerio) embryo test to discriminate between chemicals of similar molecular structure-a study with valproic acid and 14 of its analogues.

Authors:  Katharina Brotzmann; Sylvia E Escher; Paul Walker; Thomas Braunbeck
Journal:  Arch Toxicol       Date:  2022-08-03       Impact factor: 6.168

9.  Study of Valproic Acid-Enhanced Hepatocyte Steatosis.

Authors:  Renin Chang; Mei-Chia Chou; Li-Ying Hung; Mu-En Wang; Meng-Chieh Hsu; Chih-Hsien Chiu
Journal:  Biomed Res Int       Date:  2016-02-29       Impact factor: 3.411

10.  Valproate inhibits mitochondrial bioenergetics and increases glycolysis in Saccharomyces cerevisiae.

Authors:  Michael Salsaa; Bianca Pereira; Jenney Liu; Wenxi Yu; Shyamalagauri Jadhav; Maik Hüttemann; Miriam L Greenberg
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.